A combination of PDT and ICI using antibodies against PD1/PDL1, CTLA4 and IDO have been investigated in preclinical studies using murine cancer models of breast, colon, renal, lung and skin, to show significant improvements in therapeutic efficacies [98,99,100,101,102]. This evidence concerns the gene CTLA4 and cancer.